Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherLetters to the Editor

The Presence of Ethanol in Radiopharmaceutical Injections

Kim Serdons, Alfons Verbruggen and Guy Bormans
Journal of Nuclear Medicine December 2008, 49 (12) 2071; DOI: https://doi.org/10.2967/jnumed.108.057026
Kim Serdons
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfons Verbruggen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Bormans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

TO THE EDITOR: As ethanol is frequently used in radiopharmaceutical injections, we were interested in the effect of ethanol by injection. Several questions crossed our mind. What is the maximum concentration of ethanol that we can inject without side effects? What is the hemolytic potential of ethanol? Can we dilute ethanol-containing injections just with water?

Ethanol can be used in radiopharmaceutical injections to enhance the solubility of highly lipophilic tracers or to decrease adsorption to vials, membrane filters, and injection syringes. More often, ethanol is present as a residual solvent from the eluent for elution of the radiopharmaceutical from a solid phase extraction cartridge or from the mobile phase used to purify the radiopharmaceutical by high performance liquid chromatography (HPLC). Using HPLC, ethanol–buffer mixtures have a relatively high viscosity that results in a high column back pressure, but ethanol has the advantage over other organic solvents of not necessarily requiring complete removal before intravenous injection of the diluted isolated HPLC fraction. After HPLC purification, ethanol can be removed from the collected fraction by evaporation, and the residue is then dissolved in or diluted with normal saline. However, this process delays the use of the radiopharmaceutical, increases the risk of radioactive contamination and the radiation dose to the manipulator, can be accompanied by partial decomposition of the tracer, and may result in adsorption of highly lipophilic tracers to the filter membrane used for sterile filtration and to the vial, rubber stopper, and syringes. An alternative is not to remove the ethanol but to dilute the isolated HPLC fraction to an acceptably low ethanol concentration. The European Medicines Agency and the U.S. Food and Drug Administration have noted that higher amounts of ethanol (more than 0.5%, the common limit on class 3 residual solvents) may be acceptable provided they are realistic in relation to manufacturing capability and good manufacturing practice (1). Indeed, several solutions of poorly soluble nonradioactive pharmaceutical compounds for injection contain ethanol as a cosolvent in concentrations of up to 20% (2). However, to safely use ethanol in radiopharmaceutical injections, one must address several questions.

Potential side effects of ethanol on injection are pain and hemolysis, depending on the concentration. To reduce the risk of pain and hemolysis, ethanol-containing formulations should be injected slowly. This will decrease the concentration at the site of injection because of rapid mixing with large volumes of blood. Depending on the concentration, ethanol also causes hemolyses by forming membrane pores in red blood cells by which the cells finally swell and burst through a colloid-osmotic mechanism. At a low concentration, ethanol protects red blood cells from hypotonic hemolysis by partitioning into the cell membrane to increase its surface area. The osmolality of ethanol is calculated to be 2,029 mOsm/kg, which means that a mixture of 1.39% ethanol in water is isotonic. A solution for injection containing 10% ethanol, a limit used in several radiopharmaceutical centers, thus would be hypertonic on a theoretic basis. However, ethanol should not be considered in calculations of osmolality as it freely diffuses through the cell membrane. Solutions of ethanol in 0.9% NaCl show no hemolysis, whereas dilution of blood with an ethanol–water (7:93 v/v) mixture induces massive hemolysis. HPLC fractions isolated during purification of radiopharmaceuticals should thus be diluted with normal saline and not with water, as the latter situation would result in a hypotonic solution and cause hemolysis. NaCl solutions are isotonic at 0.9% (normal saline), but red blood cells are resistant to lysis in hypertonic solutions of NaCl up to 3.6%. Many cosolvents show drastic changes in hemolytic potential as the concentration of NaCl in the aqueous component increases, but the hemolytic potential of ethanol is fairly constant when mixed with 0.9%−2% NaCl solutions (3).

Injections of radiopharmaceutical preparations rarely exceed 20 mL. For a 10% ethanol solution, which is frequently used and generally accepted, a 20-mL injection would mean the administration of 2 mL of ethanol, resulting in a temporary and rapidly decreasing blood concentration of 0.44 per mille (assuming a blood volume of 4.7 L for a 70-kg adult). This is below the 0.5‰ driver's limit in force in many European countries. Special attention should be paid to injections for children, women during pregnancy and lactation, persons with alcoholism, and high-risk groups such as persons with liver disease or epilepsy.

For some preparations such as 18F-FDG, the presence of ethanol has been shown to reduce radiolysis, which may be an additional advantage of including ethanol in the formulation of radiopharmaceuticals (4).

In conclusion, ethanol is the preferred organic solvent in the mobile phases used for HPLC purification of short-lived radiopharmaceuticals, as isolated HPLC fractions can safely be used without removal of the organic solvent after appropriate dilution with normal saline to a concentration of ethanol not exceeding 10% and an injection volume below 20 mL.

Footnotes

  • COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

References

  1. 1.↵
    Guidance for industry on Q3C impurities: residual solvents (CPMP/ICH/283/95). Available at: http://www.emea.europa.eu/pdfs/human/ich/028395en.pdf or http://www.fda.gov/cber/gdlns/q3cresolvent.pdf. Accessed September 17, 2008.
  2. 2.↵
    Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–230.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Reed KW, Yalkowsky SH. Lysis of human red blood cells in the presence of various cosolvents. III. The relationship between hemolytic potential and structure. J Parenter Sci Technol. 1987;41:37–39.
    OpenUrlPubMed
  4. 4.↵
    Kiselev MY, Tadino V. Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F. W.O. 2004/043497 A1. May 27, 2004.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 49 (12)
Journal of Nuclear Medicine
Vol. 49, Issue 12
December 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Presence of Ethanol in Radiopharmaceutical Injections
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Presence of Ethanol in Radiopharmaceutical Injections
Kim Serdons, Alfons Verbruggen, Guy Bormans
Journal of Nuclear Medicine Dec 2008, 49 (12) 2071; DOI: 10.2967/jnumed.108.057026

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Presence of Ethanol in Radiopharmaceutical Injections
Kim Serdons, Alfons Verbruggen, Guy Bormans
Journal of Nuclear Medicine Dec 2008, 49 (12) 2071; DOI: 10.2967/jnumed.108.057026
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 161Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of 161Tb into the Clinic
  • Google Scholar

More in this TOC Section

  • Redefining Nuclear Medicine: “Biodistribution” Should Be the Core Concept
  • Reply to “Routine Dosimetry: Proceed with Caution”
  • Reply to “176Lu Radiation in Long–Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety”
Show more Letters to the Editor

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire